Havana, Oct 27 (RHC) The Finlay Vaccine Institute of Cuba informed this Tuesday through its Twitter account that the Center for State Control of Drugs, Equipment and Medical Devices (Cecmed) of Cuba certified the phase I clinical trial for the Covid-19, Sovereign 02 vaccine candidate.
Recently, the director of the Finlay Institute, Vicente Vérez, affirmed in an interview to the Granma newspaper that the new vaccination candidate is what is called a conjugated vaccine, which is aimed not only at the prophylaxis of Covid-19, but also of other diseases, and it is unprecedented among all those developed to face the coronavirus SARS-CoV-2, which causes Covid-19.
We hope that Soberana 02’s immunity will reach the respiratory tract mucosa to prevent the virus from entering, and it will be the vaccine candidate that we will propose to apply in the pediatric population,’ he said.
Likewise, he detailed that both Soberana 01 and Soberana 02, Cuban medicines in process against Covid-19, are molecular or subunit vaccines.
Sovereign 02 is based on a tetanus toxoid protein, a platform already tested previously by the Finlay Institute, leader in Cuba in the production of vaccines.
According to the trial’s record, it will have two groups, both of them experimental. The groups will be administered, with 28 days of difference, different doses of the Sovereign 02 vaccine candidate in a total of 40 volunteers. Thus, there will not be a control group in this phase.
As it already happened with Soberana 01, this new clinical trial is led by a woman: Dr. C. María Eugenia Toledo Romaní, from the Institute of Tropical Medicine “Pedro Kourí”, in Havana.
Cuba is the only country in Latin America, the Caribbean and Africa to register clinical trials with its own vaccine candidates against Covid-19, which is the result of the island’s biotechnology industry, all of it public.
(Taken from RHC)